库马林衍生物通过抗菌活性改善肠道炎症和感染性结肠炎模型中的致病性肠道微生物组变化
Hui-Su Jung1, Yei Ju Park2, Bon-Hee Gu3
1Laboratory of Animal Immunology, Department of Animal Science, College of Natural Resource & Life Science, Pusan National University, Miryang, Republic of Korea.
Frontiers in cellular and infection microbiology
|July 31, 2024
概括
库马林衍生物C1显示强烈的抗菌活性,减少肠道炎症和恢复微生物组平衡在感染性结肠炎模型. 这种化合物有效地对抗致病微生物,并支持有益细菌.
科学领域:
- 自然产品化学 自然产品化学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 库马林是植物衍生的化合物,具有多样化的生物活性.
- 库马林衍生物可以通过像佩克曼凝结这样的方法来合成.
- 了解它们的抗微生物和免疫调节作用对于治疗开发至关重要.
研究的目的:
- 研究合成库马林衍生物的抗菌和肠道免疫调节功能.
- 为了评估在感染性结肠炎模型中选择氨酸衍生物的疗效.
- 探索氨酸衍生物对肠道微生物组合和功能的影响.
主要方法:
- 通过Pechmann凝结合成库马林衍生物.
- 在体外抗微生物测定对各种病原性微生物.
- 在体内研究使用感染性结肠炎小鼠模型.
- 对肠道免疫细胞种群,细胞因子水平和肠道微生物组合的分析.
主要成果:
- 库马林衍生物C1和C2在体外表现出显著的抗菌活性,破坏细菌细胞膜.
- 在体内给药C1减少了病原体负载,炎症性免疫细胞 (Th1,Th17) 和细胞因子 (IL-6,IL-1b) 在结肠炎模型中.
- C1治疗将致病性微生物的扩张 (例如,Enterobacteriaceae,Staphylococcaceae) 降至最低,并促进有益的细菌 (例如,Ligilactobacillus,Limosilactobacillus).
- 功能性基因分析表明C1保留了因感染而破坏的脂质和核酸代谢途径.
结论:
- 库马林衍生物C1显示出强大的抗菌性质.
- C1有效地减轻了病原体诱导的肠道炎症和失生症.
- 这些发现表明C1是治疗肠道感染和相关炎症的有希望的治疗剂.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
114
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
114


